Vitamins D3 2500 IU (62.5 mcg) & K2 120 mcg
Goals
$14.24 $0.15 per serving
Product analysis
Vitamins D3 2500 IU (62.5 mcg) & K2 120 mcg supports normal calcium use and bone maintenance, especially when intake is low.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality67
The K2 is supplied as MK-7, a favorable form in this combination. The available information does not fully establish the quality of the vitamin D form.
Ingredient Transparency100
Both nutrient amounts and forms are clearly disclosed. That makes it easy to compare the combination with your nutritional needs.
Value For Money67
The K2 component offers favorable value at the serving price. Value for the vitamin D component remains uncertain, so the full combination cannot be judged as precisely.
Customer Satisfaction90
Customer feedback is very positive across several thousand ratings. The substantial review base supports confidence in the satisfaction pattern without proving health outcomes.
Product Focus78
The two nutrients fit a clear role in bone and mineral nutrition. The MK-7 amount is below that used in some longer trials, so their findings cannot be assumed to apply equally here.
- Format
Tablet - Container
- 90 Tablet(s)
- Per serving
- $0.15
- Customer rating
- 4.8 · 4,174 ratings
Goals
Impact
Highest effect
Vitamin D · 62.5 mcgVitamin K · 120 mcg
Vitamin D and Vitamin K contribute to mineral nutrition and bone maintenance. The nutritional contributions are most useful when intake is low; extra benefit with adequate intake is not established.
How this product is rated for Everyday Health
Ingredient fit94
Vitamin D and the other relevant nutrients provide the main connection to general health. The formula is focused on the supported nutritional contribution.
Goal fit
The supported ingredients are focused on general-health nutrition, although the product is linked to several goals.
Dose adequacy
The relevant amounts reach the saved nutritional comparison endpoints; larger amounts do not establish greater benefit.
Pathways60
The strongest area is bone and mineral metabolism. Contributions also reach the saved coverage level across bone and mineral metabolism.
Depth
The strongest supported area is bone and mineral metabolism, through the relevant nutrient contributions.
Breadth
The supported areas reaching the saved coverage level are bone and mineral metabolism.
Evidence82
Vitamin D provides the strongest supported contribution. The supplied context limits routine expectations to filling nutritional gaps rather than improving outcomes in adequately nourished adults.
Evidence strength
Vitamin D provides the strongest supported contribution here; usefulness remains conditional on the relevant nutritional or population context.
Studied preparation
The relevant preparations match those recognized by the saved findings; this does not establish superiority of a form or delivery method.
Formulation logic100
The relevant ingredients can contribute independently, and no configured conflict was found. Their presence together does not establish an added combination benefit.
Partner coverage
The relevant ingredients can contribute independently or have their required partners present; no extra combination benefit is established.
Conflicts
No configured ingredient conflict was identified in the supplied findings.
Effective doses
All ingredients retained for contribution meet the saved amount threshold; that threshold does not prove a clinical benefit.
Impact
High effect
Vitamin K · 120 mcgVitamin D · 62.5 mcg
Vitamin D helps maintain muscle function when low vitamin D is corrected, without establishing extra aging benefit when intake is adequate. The MK-7 declaration does not identify the MenaQ7 preparation studied for selected arterial-stiffness outcomes in postmenopausal women. Combining D3 and K2 does not itself establish that preparation’s effects, prevention of cardiovascular events or longer life.
How this product is rated for Longevity
Ingredient fit90
The formula has nutritional ingredients relevant to maintaining function, within a broader product. Amounts and preparation limits affect the retained findings.
Goal fit
The relevant nutrients sit within a broader formula with ingredients intended for other purposes.
Dose adequacy
The retained amounts contribute unevenly to the supplied comparisons; these are not proven doses for slowing aging.
Pathways13
The retained findings concentrate on arterial calcification control. They do not establish broad preservation across the other aging-related functions.
Depth
The strongest retained area is arterial calcification control, which does not establish an overall slowing of aging.
Breadth
No area reaches the supplied coverage benchmark; this does not mean the ingredient lacks nutritional value.
Evidence74
Vitamin D leads the retained comparison, with functional benefit tied to correcting low vitamin D rather than extra benefit in replete adults.
Evidence strength
Vitamin D leads the retained comparison, with functional benefit tied to correcting low vitamin D rather than extra benefit in replete adults.
Studied preparation
Vitamin K lacks a matching studied preparation in the retained comparison; the other retained preparations match.
Formulation logic100
The retained contributions have no missing required partners or configured conflicts, and their amounts meet the minimum comparison.
Partner coverage
No required partner is missing among the retained contributions; this does not establish extra benefit from combining them.
Conflicts
No configured ingredient conflict was identified in the supplied facts.
Effective doses
The retained ingredients meet the supplied minimum amount comparison, which is not a proven threshold for slower aging.
Impact
Highest effect
Vitamin K · 120 mcgVitamin D · 62.5 mcg
Vitamin D supports calcium absorption and normal mineralization, especially when intake is inadequate. MK-7 helps activate bone proteins and has limited, mixed findings for bone density in postmenopausal women. The 120 mcg MK-7 serving is below the 180 mcg daily amount used in a three-year trial, limiting transfer of its findings. The 62.5 mcg vitamin D serving receives full amount recognition without establishing added benefit from a higher intake.
How this product is rated for Bone Health
Ingredient fit87
Vitamin D and identified MK-7 provide a focused formula; MK-7 receives partial amount recognition.
Goal fit
Both counted ingredients are relevant to bone health, though linked to other goals.
Dose adequacy
Vitamin D receives full amount recognition, while MK-7 is below the amount in the cited trial.
Pathways80
Calcium absorption and bone-protein activation are represented, without a confirmed mineral-supply contribution.
Depth
Calcium absorption and regulation is the strongest saved area.
Breadth
Calcium absorption and bone-protein activation both meet the coverage criterion.
Evidence98
MK-7 provides the strongest saved evidence finding, with both preparations recognized.
Evidence strength
MK-7 supplies the strongest saved evidence, limited to mixed postmenopausal bone-density findings.
Studied preparation
The declared vitamin D and MK-7 are recognized preparations.
Formulation logic92
Vitamin D's calcium partner is absent; no configured conflict was found.
Partner coverage
Vitamin D lacks a confirmed calcium partner in the supplied formula.
Conflicts
No configured ingredient conflict was identified.
Effective doses
Both counted vitamins reach the saved amount criterion.
Impact
High effect
Vitamin K · 120 mcgVitamin D · 62.5 mcg
MK-7 has limited support for arterial-stiffness changes, rather than established prevention of cardiovascular events. Vitamin D has not demonstrated a reduction in major cardiovascular events, and an added D/K benefit is not established.
How this product is rated for Heart Health
Ingredient fit85
Vitamin K, Vitamin D connect to heart-related functions. Some amounts provide only partial exposure relative to the supplied comparisons.
Goal fit
Vitamin K, Vitamin D provide the relevant connection; the product's broader ingredient and goal mix limits its focus.
Dose adequacy
Vitamin K provide partial exposure compared with the supplied comparison ranges; this does not establish an ineffective dose.
Pathways44
The clearest connection is arterial calcification control. Support is concentrated in that route.
Depth
The strongest represented route is arterial calcification control, with support limited to the ingredients and amounts supplied.
Breadth
The findings cover one route, with limited breadth beyond that mechanism.
Evidence77
The supplied findings support nutrient or surrogate roles more clearly than general cardiovascular-event prevention.
Evidence strength
The supplied findings support nutrient or surrogate roles more clearly than general cardiovascular-event prevention.
Studied preparation
The eligible declared ingredients meet the supplied preparation comparison; this does not establish superiority over other forms.
Formulation logic100
The relevant ingredients do not require another partner, and no specified conflict was identified. The amount comparisons do not establish added benefit from combining ingredients.
Partner coverage
The relevant ingredients can contribute without an additional required partner; no extra combination benefit is established.
Conflicts
No specified ingredient conflict was identified in the supplied findings.
Effective doses
The ingredients included in this finding clear the supplied minimum exposure comparison; this is not a proven clinical efficacy threshold.
Impact
High effect
Vitamin K · 120 mcgVitamin D · 62.5 mcg
MK-7 has limited evidence for improvement in selected arterial-stiffness measures, chiefly from a three-year study in postmenopausal women using 180 mcg daily. This serving provides 120 mcg and receives a partial contribution; it does not establish prevention of arterial calcification or cardiovascular events. Vitamin D receives amount recognition, but routine supplementation has not reduced major cardiovascular events in the supplied evidence. No added D3 and K2 benefit is established.
How this product is rated for Cardiovascular Support
Ingredient fit85
MK-7 provides a main recognized connection, with amount and evidence limits specific to the ingredient.
Goal fit
The main active ingredients have a direct connection to the cardiovascular roles evaluated.
Dose adequacy
MK-7's 120 mcg serving is below the 180 mcg daily study amount; vitamin D receives full amount recognition.
Pathways44
The strongest finding concerns arterial stiffness. Other evaluated routes are less well covered.
Depth
The strongest contribution is assigned to arterial stiffness; that assignment does not establish prevention of cardiovascular events.
Breadth
Only arterial stiffness has broad coverage in the saved findings.
Evidence69
MK-7 supplies the leading evidence basis, with outcomes and population limitations described for its contribution.
Evidence strength
MK-7 is the strongest contributor in these findings; the underlying evidence does not establish general cardiovascular-event prevention.
Studied preparation
The identified MK-7 preparation is recognized; this does not establish added benefit from combining it with vitamin D.
Formulation logic100
Recognized contributors have their required partner support or can contribute independently. No assessed conflict was applied.
Partner coverage
Each recognized contributor can contribute independently or has its required partner; this does not demonstrate synergy.
Conflicts
The supplied facts trigger none of the evaluated stimulant or high-sodium conflicts.
Effective doses
All counted contributors meet the saved amount threshold; it is not a proven clinical efficacy threshold.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin D3 (Cholecalciferol) | 62.5 mcg | |
Vitamin K2 (Menaquinone-7) | 120 mcg |
Vitamin K (Menaquinone-7) · 120 mcg OverallScore93
Each serving provides 120 mcg of vitamin K as MK-7 at a low cost. The amount and form are clearly stated. The MK-7 isomer is unspecified.
How this ingredient is rated
Active Ingredient Quality & Bioavailability82
The vitamin K is K2 as MK-7. The MK-7 is listed without a trans or all-trans designation.
Vitamin K Form (MK-7 vs. MK-4 vs. K1)
The vitamin K is K2 as MK-7.
MK-7 Isomer Disclosure
The MK-7 is listed without a trans or all-trans designation.
Dose, Safety & Label Transparency100
A serving provides 120 mcg of MK-7. The label states the MK-7 form and amount.
Vitamin K2 (MK-7) Dosage Efficacy
A serving provides 120 mcg of MK-7.
Form and Subtype Transparency
The label states the MK-7 form and amount.
Value100
The cost per serving is low.
Price per Effective MK-7 Serving
The cost per serving is low.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Pregnancy vitamin D supplementation and offspring bone mineral density in childhood follow-up of a randomized controlled trial.
- Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.
- Efficacy of vitamin D fortified foods on bone mineral density and serum bone biomarkers: A systematic review and meta-analysis of interventional studies.
- Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial.
- Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations.
- Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
- Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
- Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
- Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
- Comparative Efficacy of Nutraceuticals on Endothelial Function: A Systematic Review and Network Meta-Analysis.
- A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD.
- Randomized, placebo-controlled, double-blind clinical trial on the contributions of vitamin D in the control of cardiovascular risk factors, depressive symptoms and suicide risk.
- Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial.
- Paricalcitol and endothelial function in chronic kidney disease trial.
- Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
- Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
- Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
- Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
- Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.